Foundation Medicine is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
!
We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue. View our Privacy Policy to learn more.
Foundation Medicine: An established portfolio of services for patients across diverse clinical situations
Foundation Medicine’s established portfolio of comprehensive genomic profiling (CGP) services should be used to inform the use of immunotherapies, identify alternative therapy options or identify trial opportunities:1–7
All of Foundation Medicine’s services use our CGP approach, which analyses the tumour genome to identify clinically relevant alterations and inform treatment decision-making.1–7
Our tests evolve as our understanding of cancer broadens
Our continuously growing genomic database currently includes over 400,000 genomic profiles across numerous tumour subtypes.10 Advanced bioinformatics interrogate the data, including fields not currently reported clinically (such as loss of heterozygosity), to generate potentially actionable insights.10
M-GB-00001595 September 2020
*Based on typical turnaround time of <2 weeks from receipt of sample.
FFPE: formalin-fixed paraffin embedded.
M-GB-00001595 September 2020
References
Frampton GM et al. Nat Biotechnol 2013;31:1023–1031.
Drilon A et al. Clin Cancer Res 2015;21:3631–3639.
Rankin A et al. Oncologist 2016;21:1306–1314.
Ross JS et al. Cancer 2016;122:2654–2662.
Suh JH et al. Oncologist 2016;21:684–691.
Hirshfield KM et al. Oncologist 2016;21:1315–1325.
Woodhouse R, et al. PLoS One. 2020;15:e-237802.
FoundationOne® CDx Technical Specifications M-GB-00001548 September 2020
FoundationOne® Liquid CDx Technical Specifications M-GB-00000169 September 2020.